US experience in evaluation and diagnosis of GH therapy of intrauterine growth retardation/small-for-gestational-age children.
The potential role of exogenous GH in treating short children born small for gestational age (SGA) has been discussed since the early 1960s. Pivotal studies in Europe during the last 10 years have shown that GH treatment of short children born SGA during childhood and early puberty (1) normalizes stature, (2) increases final height above predicted height and (3) allows children to reach their target height. A study now under way in the USA will provide additional much needed data about efficacy and safety of GH treatment in intrauterine growth retardation/SGA.
Saenger
Paul
P
Department of Pediatrics, Division of Pediatric Endocrinology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY 10467, USA. phsaenger@aol.com
D000328:Adult; D001827:Body Height / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy*; D006130:Growth Disorders / Q000188:drug therapy / Q000209:etiology; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D017566:Microvascular Angina / Q000150:complications / Q000209:etiology; D011247:Pregnancy; D014481:United States
D013006:Growth Hormone